Euro Pacific Asset Management LLC Sells 2,006 Shares of Novartis AG (NYSE:NVS)

Euro Pacific Asset Management LLC lowered its stake in shares of Novartis AG (NYSE:NVS) by 2.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 95,218 shares of the company’s stock after selling 2,006 shares during the quarter. Novartis accounts for 2.0% of Euro Pacific Asset Management LLC’s holdings, making the stock its 21st biggest holding. Euro Pacific Asset Management LLC’s holdings in Novartis were worth $9,279,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in NVS. Legacy Investment Solutions LLC purchased a new position in Novartis during the 3rd quarter valued at $28,000. Fortitude Family Office LLC grew its stake in Novartis by 503.8% in the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock valued at $37,000 after purchasing an additional 267 shares during the last quarter. Clean Yield Group bought a new position in shares of Novartis during the 3rd quarter worth approximately $43,000. Brooklyn Investment Group acquired a new position in shares of Novartis during the fourth quarter worth $55,000. Finally, Versant Capital Management Inc raised its stake in Novartis by 782.0% in the fourth quarter. Versant Capital Management Inc now owns 785 shares of the company’s stock valued at $76,000 after buying an additional 696 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Trading Down 0.1 %

Shares of NVS opened at $99.93 on Friday. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92. The firm has a market capitalization of $204.25 billion, a P/E ratio of 11.61, a P/E/G ratio of 1.42 and a beta of 0.57. The firm has a 50-day moving average price of $100.15 and a 200 day moving average price of $108.75. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. The business had revenue of $12.82 billion during the quarter, compared to analysts’ expectations of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same quarter in the prior year, the company posted $1.74 EPS. Sell-side analysts forecast that Novartis AG will post 7.62 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on NVS. Erste Group Bank restated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. BMO Capital Markets increased their target price on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Finally, HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.